title: A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5 mg and Pravastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1).
abstract: OBJECTIVE
  For new evidence of treatment with statins in Japanese hypercholesterolemic patients, we performed an open-label, randomized, parallel-group comparative study to assess the effect of rosuvastatin 2.5 mg and pravastatin 10 mg on plasma lipids.
  
  
  METHODS
  A total of 100 patients in whom the target control levels of LDL-cholesterol (LDL-C) set by the Japan Atherosclerosis Society Guidelines (JASGL2007) had not been achieved were randomly assigned to receive rosuvastatin 2.5 mg / day or pravastatin 10 mg / day for 8 weeks. The primary endpoint was the percent change of LDL-C at week 8.
  
  
  RESULTS
  LDL-C was lowered by -40.3% (from 160.3 to 95.1 mg / dL) in the rosuvastatin group and -22.9% (from 162.9 to 126.0 mg / dL) in the pravastatin group, at week 8 (P < 0.001 vs. pravastatin). LDL-C / HDL-C ratio was lowered by -41.3% (from 2.85 to 1.69) and -20.6% (from 2.81 to 2.24), respectively (P < 0.001 vs. pravastatin). The rate of achievement of the target LDL-C control level at week 8 was significantly higher in the rosuvastatin group (98.0%) than in the pravastain group (78.7%) (P = 0.003). Both drugs were well tolerated.
  
  
  CONCLUSIONS
  Rosuvastatin 2.5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than pravastatin 10 mg, and its safety profile is similar to pravastatin 10 mg.
authors.affiliation: Department of Clinical Epidemiology and Systems, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kurabayashi
keywords: LDL-C; LDL-C / HDL-C ratio; Statin; guideline
references.citation: Am J Cardiol. 2003 Jul 15;92(2):152-60
references.pmid: 12860216
references.citation: J Cardiovasc Risk. 2001 Dec;8(6):383-90
references.pmid: 11873095
references.citation: JAMA. 2007 Feb 7;297(5):499-508
references.pmid: 17284700
references.citation: JAMA. 1997 Jul 23-30;278(4):313-21
references.pmid: 9228438
references.citation: N Engl J Med. 1996 Oct 3;335(14):1001-9
references.pmid: 8801446
references.citation: J Atheroscler Thromb. 2002;9(1):48-56
references.pmid: 12238638
references.citation: JAMA. 2006 Apr 5;295(13):1556-65
references.pmid: 16533939
references.citation: Lancet. 1994 Nov 19;344(8934):1383-9
references.pmid: 7968073
references.citation: J Atheroscler Thromb. 2004;11(3):152-8
references.pmid: 15256766
references.citation: Lancet. 2003 Apr 5;361(9364):1149-58
references.pmid: 12686036
references.citation: Curr Ther Res Clin Exp. 2005 Mar;66(2):80-95
references.pmid: 24672115
references.citation: JAMA. 2001 May 16;285(19):2486-97
references.pmid: 11368702
references.citation: J Atheroscler Thromb. 2007 Oct;14(5):209-12
references.pmid: 17986796
references.citation: Circulation. 2001 Jan 23;103(3):357-62
references.pmid: 11157685
references.citation: J Atheroscler Thromb. 2003;10(6):329-36
references.pmid: 15037821
references.citation: N Engl J Med. 1995 Nov 16;333(20):1301-7
references.pmid: 7566020
references.citation: J Atheroscler Thromb. 2007 Apr;14(2):45-50
references.pmid: 17485887
references.citation: Lancet. 2006 Sep 30;368(9542):1155-63
references.pmid: 17011942
references.citation: Lancet. 2004 Aug 21-27;364(9435):685-96
references.pmid: 15325833
references.citation: J Cardiol. 2005 Jan;45(1):1-10
references.pmid: 15700924
references.citation: JAMA. 1998 May 27;279(20):1615-22
references.pmid: 9613910